-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
-
-
-
-
-
-
-
EyePoint Inc. (EYPT) PT Raised to $30 at H.C. Wainwright
-
-
-
-
-
-
-
RBC Capital on EyePoint Inc. (EYPT): 'we see weighted avg. upside of ~60% into EYPT's wAMD Phase III readout'
-
-
-
-
-
-
-
EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c
-
-
-
-
-
-
-
JPMorgan on EyePoint Pharmaceuticals, Inc. (EYPT): 'We are pleased to see EyePoint’s continued execution'
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
-
-
-
-
-
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $33 at Baird
-
439,058 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

